The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial

Author(s): Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, et al.

Abstract

To determine whether the functional mu-opioid receptor (OPRM1) Asn40Asp variant predicts the comparative efficacy of different forms of NRT, we conducted a clinical trial of transdermal nicotine (TN) vs nicotine nasal spray (NS) in 320 smokers of European ancestry. Smokers carrying the OPRM1 Asp40 variant (n=82) were significantly more likely than those homozygous for the Asn40 variant (n=238) to be abstinent at the end of treatment, and reported less mood disturbance and weight gain. The genotype effect on treatment outcome was most pronounced among smokers receiving TN, particularly during the 21 mg dose phase. Smokers who carry the OPRM1 Asp40 variant are likely to have a favorable response to TN and may benefit from extended therapy with the 21 mg dose.

Similar Articles

Personality and the perception of health and happiness

Author(s): Cloninger CR, Zohar AH

J Pers Soc Psychol 54: 1063-1070

Author(s): Watson D, Clark LA, Tellegen A (1988a) Development and validation of brief measures of positive and negative affect: the PANAS scales

Cohort Profile: LifeLines, a three-generation cohort study and biobank

Author(s): Scholtens S, Smidt N, Swertz MA, Bakker SJ, Dotinga A, et al.

Pleasures of the brain

Author(s): Berridge KC

The pleasures of play: pharmacological insights into social reward mechanisms

Author(s): Trezza V, Baarendse PJJ, Vanderschuren LJMJ

The neuro-symphony of stress

Author(s): Joëls M, Baram TZ

Stereotype threat and social function in opioid substitution therapy patients

Author(s): Henry JD, von Hippel C, Terrett G, Mercuri K, McAlear K, et al.

Delta Opioid Receptor Signaling Promotes Resilience to Stress Under the Repeated Social Defeat Paradigm in Mice

Author(s): Henry MS, Bisht K, Vernoux N, Gendron L, Torres-Berrio A, et al.

Global Approaches in the Analysis of Cocaine-Induced Gene Expression

Author(s): Eipper-Mains JE, Eipper BA, Mains RE

Nicotine dependence is characterized by disordered reward processing in a network driving motivation

Author(s): Bühler M, Vollstädt-Klein S, Kobiella A, Budde H, Reed LJ, et al.

State-dependent µ-opioid Modulation of Social Motivation–a model

Author(s): Loseth GE, Ellingsen DM, Leknes S

Attacking pain at its source: new perspectives on opioids

Author(s): Stein C, Schafer M, Machelska H

Opioid system and human emotions

Author(s): Nummenmaa L, Tuominen L

Dynorphin, stress, and depression

Author(s): Knoll AT, Carlezon Jr WA

The role of the dynorphin/κ opioid receptor system in anxiety

Author(s): Hang Ai, Wang YJ, He L, Liu JG

Corticolimbic anatomical characteristics predetermine risk for chronic pain

Author(s): Vachon-Presseau E, Tétreault P, Petre B, Huang L, Berger SE, et al.

The Genome of the Netherlands: design, and project goals

Author(s): Boomsma DI, Wijmenga C, Slagboom EP, Swertz MA, Karssen LC, et al.

PLINK: a tool set for whole-genome association and population-based linkage analyses

Author(s): Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al.

Exome sequencing-driven discovery of coding polymorphisms associated with common metabolic phenotypes

Author(s): Albrechtsen A, Grarup N, Li Y, Sparsø T, Tian G, et al.

J Abnorm Psychol 97: 346-353

Author(s): Watson D, Clark LA, Carey G (1988b) Positive and negative affectivity and their relation to anxiety and depressive disorders

Modeling genetic imprinting effects of DNA sequences with multilocus polymorphism data

Author(s): Wen S1, Wang C, Berg A, Li Y, Chang MM, et al.

Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats

Author(s): Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, et al.

Psychotomimesis mediated by kappa opiate receptors

Author(s): Pfeiffer A, Brantl V, Herz A, Emrich HM

Fast and accurate genotype imputation in genome-wide association studies through pre-phasing

Author(s): Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR